Comparison of the expected rewards between probabilistic and deterministic analyses in a Markov model

ABSTRACT Objectives: In Markov models that evaluate the cost-effectiveness of health-care technologies, it is generally recommended to use probabilistic analysis instead of deterministic analysis. We sought to compare the performance of probabilistic and deterministic analysis in estimating the expected rewards in a Markov model. Methods: We applied Jensen’s inequality to compare the expected Markov rewards between probabilistic and deterministic analysis and conducted a simulation study to compare the bias and accuracy between the two approaches. Results: We provided mathematical justification why probabilistic analysis is associated with greater Markov rewards (life-years and quality-adjusted life-years) compared with deterministic analysis. In our simulations, probabilistic analyses tended to generate greater life-years, bias, and mean square error for the estimated rewards compared with deterministic analyses. When the expected values of transition probabilities were the same, weaker evidence derived from smaller sample sizes resulted in larger Markov rewards compared with stronger evidence derived from larger sample sizes. When longer time horizons were applied in cases of weak evidence, there was a substantial increase in bias where the rewards in both probabilistic and deterministic analysis were overestimated. Conclusion: Authors should be aware that probabilistic analysis may lead to increased bias when the evidence is weak.

[1]  M. Sculpher,et al.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.

[2]  Michael J Crowther,et al.  Using simulation studies to evaluate statistical methods , 2017, Statistics in medicine.

[3]  John D. Graham,et al.  Going beyond the single number: Using probabilistic risk assessment to improve risk management , 1996 .

[4]  Karl Claxton,et al.  Exploring Uncertainty in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.

[5]  B. McNeil,et al.  Probabilistic Sensitivity Analysis Using Monte Carlo Simulation , 1985, Medical decision making : an international journal of the Society for Medical Decision Making.

[6]  Joshua T. Cohen,et al.  The influence of time horizon on results of cost-effectiveness analyses , 2017, Expert review of pharmacoeconomics & outcomes research.

[7]  J. Chhatwal,et al.  Characterizing Heterogeneity Bias in Cohort-Based Models , 2015, PharmacoEconomics.

[8]  Andrew Briggs,et al.  Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  A. Mcd A variant of Jensen''s inequality , 2003 .

[10]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .

[11]  Karl Claxton,et al.  Probabilistic analysis and computationally expensive models: Necessary and required? , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  J. Olsen,et al.  Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010 , 2014, PharmacoEconomics.

[13]  Patrick Royston,et al.  The design of simulation studies in medical statistics , 2006, Statistics in medicine.